Saranas Receives FDA Approval in March, and already reaches another milestone

Early Bird Bleed Monitoring System developed by Saranas, a GOOSE portfolio company, at the Texas Heart Institute in Houston received a much-anticipated FDA approval in March 2019. Saranas Early Bird Bleed Monitoring System detects bleeding in real-time, allowing doctors to act quickly and improve the outcomes of the procedures and recovery of the patient.  

This month, Saranas reached another milestone as a new study validates the effectiveness of the Saranas Early Bird Bleed Monitoring System. The system successfully detected bleeding events during endovascular related procedures on 60 patients enrolled in the study.

This is very important news for patients who need transcatheter aortic valve replacement, or other large-bore endovascular procedures. Currently, one in five patients experience bleeding complications during these procedures. Saranas Early Bird Monitoring System significantly reduces risk of mortality, length of hospital stays, and healthcare costs caused by bleeding complications. 

Philippe Genereux, MD, principal investigator, cardiologist and physician at Morristown Medical Center in Morristown, NJ commented on the study results: “This is the first time we’re seeing how this device could help in a real-world patient setting, and we were very encouraged by the results. Right now, patients have a risk of vessel injury when undergoing endovascular procedures where the femoral artery or vein is used for vascular access.” GOOSE is extremely excited about the news. We look forward to support Saranas in reaching their next goals.

Texas A&M New Ventures Competition

On May 15th and 16th of 2019, GOOSE participated in the Texas A&M New Ventures Competition for the second year in a row. The competition, organized by Texas A&M Engineering Experiment Station, the Texas A&M University System, and a growing number of sponsors (including GOOSE), aims to promote and commercialize Texas based companies with innovative ideas. The competition recognized companies focused on emerging technologies, with high-growth potential. GOOSE and other sponsors provide cash and investment prizes to help the companies execute their ideas and advance the product development.

The prize pool for this year’s competition was the largest yet, exceeding $500,000. Twenty-two Texas startups competed for the prizes. This year, Spark Biomedical was awarded the grand prize: $50,000. Spark Biomedical is a medical device company developing non-invasive neurostimulation solutions for opioid withdrawal and addiction.

Goose members David Klein and Larry Lawson judged the competition and were very impressed with the competitors. GOOSE awarded PolyVascular a $25,000 prize with potential for more. PolyVascular is developing a polymeric transcatheter valve for children. The transcatheter polymeric valves by PolyVascular are unique, because they expand as the child grows. That eliminates the need of repeat open heart surgeries for children with congenital heart disease. In addition to the GOOSE investment prize, PolyVascular won three other awards:

  • 1st place in the Elevator Pitch Competition – $5,000
  • Biotex Investment Prize
  • Amerra Visualization Services Prize

GOOSE is very optimistic about the future of the company. We look forward to working with PolyVascular.

David Klein awarding the GOOSE invetment prize to PolyVascular. From the left:  Chris Scotti, PolyVascular Team: Daniel Harrington – CSO, Kwonsoo Chun – CTO, Henri Justino – CMO, David Klein – GOOSE.

Scroll to top